Kabra Drugs Ltd
Kabra Drugs Ltd (KABRADG) last traded at ₹21.7, a market capitalisation of ₹51.3 crore, on a P/E of 6.76. Over the past 52 weeks the stock has ranged between ₹15.5 and ₹35.5. Kabra Drugs Ltd last reported results for the quarter ended Jun 2026, with sales of ₹46.22 crore and net profit of ₹2.12 crore. Figures are as of 25 Aug 2026 and are not real time.
Kabra Drugs Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Kabra Drugs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹46.22 cr, up 546.4% from ₹7.15 cr a year earlier. Net profit turned positive at ₹2.12 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 7.15 | 19.76 | 30.42 | 35.41 | 46.22 |
| Expenses | 0.4 | 0.53 | 0.24 | 7.67 | 17.72 | 27.99 | 34.07 | 43.43 |
| Operating profit | -0.4 | -0.53 | -0.24 | -0.52 | 2.04 | 2.43 | 1.34 | 2.79 |
| OPM % | — | — | — | -7.27% | 10.32% | 7.99% | 3.78% | 6.04% |
| Other income | 0 | 0 | 0.64 | 0.02 | 0.18 | 0.18 | 0.11 | 0.08 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 |
| Depreciation | 0 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0.02 | 0.02 |
| Profit before tax | -0.4 | -0.53 | 0.39 | -0.5 | 2.21 | 2.6 | 1.42 | 2.84 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 16.74% | 1.54% | 25.35% | 25.35% |
| Net profit | -0.4 | -0.54 | 0.39 | -0.5 | 1.84 | 2.57 | 1.06 | 2.12 |
| EPS (₹) | -0.40 | -0.54 | 0.16 | -0.21 | 0.78 | 1.08 | 0.45 | 0.89 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Kabra Drugs Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 93 | 132 |
| Operating profit | -0 | -0 | -0 | -1 | -2 | 5 | 9 |
| OPM % | — | — | -3,400% | — | — | 6% | 7% |
| Net profit | -0 | -0 | -0 | -1 | -1 | 5 | 8 |
| EPS (₹) | -0.41 | -0.43 | -0.77 | -1.69 | -0.46 | 2.09 | 3.20 |
TTM is the trailing twelve months to the most recent quarter.
Kabra Drugs Ltd growth and returns
- 10 Years
- 25%
- 5 Years
- %
- 3 Years
- %
- TTM
- 1744%
- 10 Years
- 67%
- 5 Years
- 97%
- 3 Years
- 155%
- TTM
- 823%
- 10 Years
- 12%
- 5 Years
- 33%
- 3 Years
- 73%
- 1 Year
- 15%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 8%
- Last Year
- 18%
Kabra Drugs Ltd shareholding pattern
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Public | 100.01% | 100.00% | 100.00% | 100.01% | 100.00% | 100.00% | 100.00% | 100.00% |
| No. of shareholders | 7,367 | 7,343 | 7,435 | 7,449 | 8,098 | 8,862 | 9,185 | 9,680 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Kabra Drugs Ltd corporate filings
- Reconstitution of the Composition of the Board & Committees of Regulation 30 of SEBI (LODR) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Kabra Drugs Ltd has filed a disclosure regarding the reconstitution of its Board of…
Read the full analysis - Newspaper Advertisement for the quarter ended on 30th June 2026.Company Updatelow impact
Cruxal's analysis: Kabra Drugs Ltd has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - Resignation of director of Ms. Anand AnithaCompany Updatelow impact
Cruxal's analysis: Aanjaay Industries Limited has formally notified the exchange regarding the resignation…
Read the full analysis - Undertaking for Non-Applicability of Reg 32Company Updatelow impact
Cruxal's analysis: Kabra Drugs Ltd has submitted an undertaking confirming that Regulation 32 of the SEBI…
Read the full analysis - Financials resultsResulthigh impact
Cruxal's analysis: Aanjaay Industries Limited reported a significant turnaround for the quarter ended 30th…
Read the full analysis - Outcome of Board Meeting held on 12th August 2026Board Meetinghigh impact
Cruxal's analysis: Aanjaay Industries Limited reported a significant improvement in financial performance…
Read the full analysis - Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Board Meeting to be held on 12-August-2026Board Meetinglow impact
Cruxal's analysis: Aanjaay Industries Limited has formally intimated the BSE regarding a Board Meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Kabra Drugs Ltd
Cruxal reads every Kabra Drugs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.